Inherited epidermolysis bullosa is a heterogeneous group of hereditary skin diseases characterized by skin (mucosa) fragility, which leads to blistering. Junctional epidermolysis bullosa is associated with mutations in genes expressing proteins of the dermo-epidermal junction. Dupilumab, an antibody that directly targets interleukin (IL)-4 receptor alpha, may be an effective treatment for dystrophic epidermolysis bullosa. We describe a case of junctional epidermolysis bullosa that improved with dupilumab.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09546634.2023.2253943 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!